# A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Study · id `cardio:ct-nct05342623` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05342623](<https://clinicaltrials.gov/study/NCT05342623>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05342623

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 286 participants.

## Technical summary

Registry record NCT05342623. Randomized; double masking; primary purpose treatment. Start 2022-05-17 (actual); primary completion 2024-02-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 286 participants (enrolled count; ClinicalTrials.gov record NCT05342623, source copy `cardio:ctgov-nct05342623-2024-05-07`, retrieved 2026-10-26)
- Started: 2022-05-17 (actual) (ClinicalTrials.gov record NCT05342623, source copy `cardio:ctgov-nct05342623-2024-05-07`, retrieved 2026-10-26)
- Primary completion: 2024-02-29 (actual) (ClinicalTrials.gov record NCT05342623, source copy `cardio:ctgov-nct05342623-2024-05-07`, retrieved 2026-10-26)
- Completion: 2024-02-29 (actual) (ClinicalTrials.gov record NCT05342623, source copy `cardio:ctgov-nct05342623-2024-05-07`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05342623, source copy `cardio:ctgov-nct05342623-2024-05-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05342623-2024-05-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
- Condition: Chronic Kidney Diseases
- Condition: Pruritus
- Intervention (Drug): Difelikefalin 1 mg Oral Tablet
- Intervention (Drug): Placebo Oral Tablet
- Lead sponsor: Cara Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Cara Therapeutics, Inc. (`cardio:org-cara-therapeutics-inc`)

## Provenance

Content hash: a2b9b5d3bbb9e561705cd6215b5569922261daaf2673b73ea15aa7ea1a0ab51d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
